Based on the extensive testing and analysis that we have done over the past 18 months – working with five independent certified laboratories, as well as third party experts and physicians - we now have a complete set of results** for the first-generation DreamStation devices.
** Philips Respironics has provided the data and analyses to the FDA and other competent authorities. The FDA is still considering the data and analyses that Philips Respironics has provided and may reach different conclusions. Healthcare providers, patients, and other stakeholders should use the complete update, including information on the limitations of the testing, for any informed decision making and should not solely rely on the overview presented here. Philips Respironics’ guidance for healthcare providers and patients remains unchanged. Philips Respironics will continue with the remediation program.
February 13, 2023
Click here to learn moreDecember 14, 2022
Click here to learn moreAugust 11, 2022
Click here to learn moreJune 28, 2022
Click here to learn moreJune 1, 2022
Click here to learn moreSeptember 3, 2021
Click here to learn moreSeptember 1, 2021
Click here to learn moreYou are about to visit a Philips global content page
ContinueYou are about to visit the Philips USA website.
I understand